Eckart Laack
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eckart Laack has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Carsten Bokemeyer
Department of Oncology and Hematology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg
2 shared publicationsGuido Sauter
Department of Pathology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg
2 shared publicationsBirte Andritzky
Department of Oncology and Hematology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg
1 shared publicationChristian Habermann
Department of Diagnostic and Interventional Radiology, Diagnostic Center, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg
1 shared publicationChristoph Zur Verth
Department of Internal Medicine, Hospital Itzehoe, Germany
1 shared publicationIna Thöm
Department of Oncology and Hematology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg
1 shared publication
Latest Publications
- Open Access
- 1 January 2011
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 6 (1) , 199-202
Miliary Never-Smoking Adenocarcinoma of the Lung: Strong Association with Epidermal Growth Factor Receptor Exon 19 Deletion
- 1 January 2011
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 6 (1) , 199-202
Open AccessMiliary Never-Smoking Adenocarcinoma of the Lung: Strong Association with Epidermal Growth Factor Receptor Exon 19 Deletion
- 21 June 2010
- Published by Elsevier in Lung Cancer
- Vol. 69 (3) , 259-264
Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer
- 21 June 2010
- Published by Elsevier in Lung Cancer
- Vol. 69 (3) , 259-264
Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer